Hermes Pharma earmarks €25M to expand oral drug production capacity

Hermes Pharma, a German CDMO, plans to spend 25 million euros ($26 million) to enhance its production capabilities for oral medicines.

The funds will be used to buy new equipment, boost efficiency, increase production capacity and add storage space, the company said in a Sept. 26 press release.

The investment is expected to drive future growth for Hermes, which manufactures easy-to-swallow oral dosage forms such as orally disintegrating granules and chewable tablets.

“As pharmaceutical companies race to find ways to better serve patients and differentiate themselves in a competitive market, we’re seeing unprecedented demand for more patient-centric products,” Andreas Ulrich, Hermes chief operating officer, said in the release.

Founded in 1907 and based in Pullach, Germany, Hermes Pharma is the sister company of Hermes Arzneimittel, which markets OTC brands. As for Hermes Pharma, the company pitches itself as a CDMO firm focused on "user-friendly dosage forms."

The company says it works with half of the top 20 pharma companies plus four leading generics players.